Clinical and biological implications of driver mutations in myelodysplastic syndromes

Short summary

Seventy-eight percent of MDS patients harbor at least one oncogenic mutation, with early spliceosome mutations predicting disease evolution and clinical phenotype.

AI-generated from the title and abstract; the full text is not read.